Pseudechis papuanus venom, the Papuan black snake, is a large, robust elapid endemic to southern New Guinea. It is a medically important species known for its potent, complex venom that causes significant systemic and local tissue damage. Encounters are relatively frequent in its range, and its bites require urgent medical attention.
Key Specifications & Components:
-
Primary Toxins: The venom is characterized by a high concentration of potent myotoxic phospholipases A₂ (PLA₂s), notably pseudechetoxin and pseudexin homologues. It also contains neurotoxins, anticoagulants, and hemolytic factors.
-
Mechanism & Clinical Effects:
-
Myotoxicity: This is the defining and most severe effect. It causes rapid and extensive rhabdomyolysis (muscle breakdown), leading to severe myalgia, muscle weakness, and myoglobinuria (dark brown urine). This poses a high risk of acute kidney injury.
-
Neurotoxicity: Can cause mild to moderate descending flaccid paralysis, including ptosis and difficulty swallowing, but this is often secondary to the profound myolysis.
-
Coagulopathy: Often induces a mild anticoagulant effect and may contribute to systemic bleeding.
-
Local Effects: Significant local pain, swelling, and potential tissue necrosis at the bite site.
-
-
Potency & Yield: Venom is moderately to highly potent with a murine LD₅₀ (subcutaneous) of approximately 0.5 – 1.0 mg/kg. It delivers a large venom yield (often 100-200 mg dry weight) due to the snake’s size, resulting in a substantial toxic dose.
-
Treatment: Primary first aid is pressure immobilization. The CSL Polyvalent Antivenom or Papuan Taipan Antivenom (both effective against Pseudechis spp.) are used. Aggressive supportive care, especially for myoglobinuria and renal protection, is crucial.
